Compartir
Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17) (en Inglés)
Basha Riyaz,Ahmad Sarfraz (Autor)
·
Academic Press
· Tapa Dura
Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17) (en Inglés) - Basha Riyaz,Ahmad Sarfraz
$ 169.85
$ 283.09
Ahorras: $ 113.23
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Reino Unido
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Jueves 08 de Agosto y el
Miércoles 21 de Agosto.
Lo recibirás en cualquier lugar de Estados Unidos entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17) (en Inglés)"
Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.
